APO-ACYCLOVIR TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
31-08-2021
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
ACYCLOVIR
Fáanlegur frá:
APOTEX INC
ATC númer:
J05AB01
INN (Alþjóðlegt nafn):
ACYCLOVIR
Skammtar:
200MG
Lyfjaform:
TABLET
Samsetning:
ACYCLOVIR 200MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100/500
Gerð lyfseðils:
Prescription
Lækningarsvæði:
NUCLEOSIDES AND NUCLEOTIDES
Vörulýsing:
Active ingredient group (AIG) number: 0115506002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
1997-08-21
Vara einkenni
_____________________________________________________________________________________
_APO-ACYCLOVIR Product Monograph _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
APO-ACYCLOVIR
ACYCLOVIR TABLETS
APOTEX STANDARD
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
APOTEX INC. DATE OF PREPARATION:
150 SIGNET DRIVE
April 10, 1997
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
August 31, 2021
Control No. 255331
_____________________________________________________________________________________
_APO-ACYCLOVIR Tablets Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..............................................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................................
6
DRUG INTERACTIONS
..........................................................................................................................................
9
DOSAGE AND ADMINISTRATION
......................................................................................................................
9
OVERDOSAGE
......................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................................
Lestu allt skjalið
